Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Stock Information for Fortress Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc.

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.